Found 1 Presentation For Request "1156p"
1156P - Quality-adjusted survival with brigatinib (BRG) versus crizotinib (CRZ) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC): Results from the ALTA-1L trial
- Maria Rosario Garcia Campelo (A Coruña, Spain)
Abstract
Background
The ALTA-1L phase III trial showed BRG significantly improved blinded independent review committee (BIRC)-assessed progression-free survival (PFS) (hazard ratio [HR]=0.48, 95% confidence interval [CI] [0.35-0.66]) and investigator (INV)-assessed PFS (HR=0.43, 95% CI [0.31-0.58]) vs CRZ in patients with
Methods
Patient survival was partitioned into three health states: time with grade 3/4 toxicity before progression (TOX), time without disease progression or grade 3/4 toxicity (TWiST), and time with disease progression (REL). Quality-adjusted time spent in each state was calculated by applying health-state utilities to the estimated mean time in that health state. Quality-adjusted PFS (QA-PFS) and quality-adjusted overall survival (Q-TWiST) were assessed. Utilities for TOX, TWiST, and REL were assigned as 0.756, 0.793, and 0.55 (0 for QA-PFS), respectively. BIRC and INV-assessed progression (PROG) were used.
Results
Compared to patients with CRZ (n = 138), patients with BRG (n = 137) had a longer mean duration of TWiST (26.1 vs 16.9 months, P<0.001) and TOX (2.3 vs 1.1 months, P=0.064) but shorter REL (10.5 vs 19.9 months, P<0.001) using BIRC-assessed PROG. Similar results of mean duration for these three health states were found using INV-assessed PROG. There were significant improvements in QA-PFS and Q-TWiST for BRG vs CRZ using BIRC and INV-assessed PROG (Table). Mean (SE) Q-TWiST and QA-PFS by BIRC and INV-assessed PROG
Q-TWiST (months) BRG CRZ Q-TWiST Gains P value BIRC PROG 28.2 (1.1) 25.1 (1.1) 3.1 (1.6) 0.045 INV PROG 28.5 (1.2) 24.8 (1.1) 3.7 (1.6) 0.018 BRG CRZ QA-PFS Gains P value BIRC PROG 22.5 (1.4) 14.2 (1.3) 8.3 (1.9) <0.001 INV PROG 23.2 (1.4) 13.1 (1.2) 10.1 (1.8) <0.001
Conclusions
In patients with advanced
Clinical trial identification
NCT02737501.
Editorial acknowledgement
Medical writing support provided by Jane Kondejewski, PhD of SNELL Medical Communication, Inc.
Legal entity responsible for the study
Takeda Development Center Americas, Inc.
Funding
Takeda Development Center Americas, Inc.
Disclosure
M.R. Garcia Campelo: Financial Interests, Institutional, Advisory Board: AstraZeneca, BMS, Novartis, Eli Lilly, MSD, Janssen, Sanofi, Pfizer, Takeda, Roche; Financial Interests, Institutional, Sponsor/Funding, Research funding: BMS; Financial Interests, Institutional, Speaker’s Bureau: AstraZeneca, BMS, Novartis, Eli Lilly, MSD, Janssen, Sanofi, Pfizer, Takeda, Roche. Y. Wan, M. Lin, T. Chen, J. Shen, P. Zhang, M.J. Humphries: Financial Interests, Institutional, Full or part-time Employment: Takeda Development Center Americas, Inc. D.R. Camidge: Financial Interests, Institutional, Advisory Board: 14ner/Elevation, AbbVie, Achilles, Amgen, Anchiarno, Anheart, Apollomics, Archer, AstraZeneca, BeiGene, BeyondSpring, Bio-Thera, Blueprint, BMS, CBT Pharmaceuticals, Daiichi Sankyo, Eisai, Elevation, Eli Lilly, EMD Serono, G1 Therapeutics, GSK, Helssin, Hengrui, Janssen, Kestrel, Medtronic, Mersana, Nuvalent, Onkure, Pfizer, Puma, Qilu, Ribon, Roche/Genentech, Sanofi, Seattle Genetics, Takeda, Turning Point; Financial Interests, Institutional, Sponsor/Funding, Research funding: Inivata; Financial Interests, Institutional, Invited Speaker, Company-sponsored trial at institution (PI role): AbbVie, AstraZeneca, Dizal, Inhibrx, Karyopharm, Pfizer, Phosplatin, Psioxus, Rain, Roche/Genentech, Seattle Genetics, Takeda, Turning Point.